Biology of Blood and Marrow Transplantation

CD19-targeted CAR-T cells Late events Hypogammaglobulinemia Cytopenia Subsequent malignancies

[1]  M. Bar,et al.  Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  M. Bar,et al.  Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  L. Schapira,et al.  Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. , 2019, Journal of pain and symptom management.

[4]  He Huang,et al.  Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  S. Sidana,et al.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  D. Maloney,et al.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.

[7]  D. Maloney,et al.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. , 2019, Blood.

[8]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  D. Porter,et al.  Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Bar,et al.  Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  G. Abel,et al.  Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[13]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[14]  S. Hashmi,et al.  Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. , 2019, Blood reviews.

[15]  Jian Yu,et al.  A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia , 2018, Bone Marrow Transplantation.

[16]  Kevin A Hay,et al.  Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor‐modified (CAR‐) T cell therapy , 2018, British journal of haematology.

[17]  D. Schadendorf,et al.  Patient-reported outcomes with nivolumab in advanced solid cancers. , 2018, Cancer treatment reviews.

[18]  C. Turtle,et al.  Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies , 2018, CNS Drugs.

[19]  Wei Zhang,et al.  Autoimmune disease-associated non-Hodgkin’s lymphoma—a large retrospective study from China , 2018, Annals of Hematology.

[20]  H. Dastani,et al.  Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. , 2018, European journal of cancer.

[21]  Hans Bitter,et al.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell , 2018, Nature Medicine.

[22]  L. Deangelis,et al.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[23]  H. Jim,et al.  Patient-reported outcomes and health status associated with chronic graft-versus-host disease , 2018, Haematologica.

[24]  C. Johansen,et al.  The Generalized Anxiety Disorder Screener (GAD‐7) and the anxiety module of the Hospital and Depression Scale (HADS‐A) as screening tools for generalized anxiety disorder among cancer patients , 2018, Psycho-oncology.

[25]  S. Jabbour,et al.  Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer. , 2018, Translational lung cancer research.

[26]  保坂隆,et al.  Psycho-oncology , 2018, Recent Results in Cancer Research.

[27]  S. Seo,et al.  Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Fairclough,et al.  PROMIS measures can be used to assess symptoms and function in long‐term hematopoietic cell transplantation survivors , 2018, Cancer.

[29]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[30]  K. Cornetta,et al.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  J. Castillo,et al.  Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B‐cell lymphomas , 2018, American journal of hematology.

[32]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[33]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[34]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[35]  S. Rosenberg,et al.  Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  D. Maloney,et al.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. , 2017, Blood.

[37]  F. Roila,et al.  Cognitive impairment and chemotherapy: a brief overview. , 2017, Critical reviews in oncology/hematology.

[38]  B. Cheson,et al.  Extended Follow‐up of Patients Treated With Bendamustine for Lymphoid Malignancies , 2017, Clinical lymphoma, myeloma & leukemia.

[39]  J. Armitage,et al.  Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population‐based Study , 2017, Clinical lymphoma, myeloma & leukemia.

[40]  K. Harrington,et al.  Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[41]  J. Byrd,et al.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Kris,et al.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.

[43]  B. Reeve,et al.  Activities, function, and health-related quality of life (HRQOL) of older adults with cancer. , 2017, Journal of geriatric oncology.

[44]  B. Reeve,et al.  United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Stephanie J. Lee,et al.  Late effects of blood and marrow transplantation , 2017, Haematologica.

[46]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[47]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[48]  E. Basch,et al.  Patient-reported outcomes in the evaluation of toxicity of anticancer treatments , 2016, Nature Reviews Clinical Oncology.

[49]  Laura Manea,et al.  Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. , 2016, General hospital psychiatry.

[50]  W. Wood,et al.  Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  S. Heimfeld,et al.  Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes , 2015 .

[52]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[53]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[54]  S. Chambers,et al.  A Meta-Analysis of Cognitive Impairment and Decline Associated with Adjuvant Chemotherapy in Women with Breast Cancer , 2015, Front. Oncol..

[55]  Kyle R. Noll,et al.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults , 2015, CA: a cancer journal for clinicians.

[56]  M. Taphoorn,et al.  Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. , 2015, Neuro-oncology practice.

[57]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[58]  R. Gershon,et al.  Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment , 2014, Quality of Life Research.

[59]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[60]  P. Sismondi,et al.  Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. , 2012, European journal of cancer care.

[61]  S. Bhatia,et al.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). , 2011, Blood.

[62]  S. Dikmen,et al.  Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  D. Cella,et al.  Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. , 2011, Journal of clinical epidemiology.

[64]  B. Kurland,et al.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.

[65]  L. Morales,et al.  Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. , 2010, Journal of clinical epidemiology.

[66]  R. Hays,et al.  Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). , 2010, Journal of clinical epidemiology.

[67]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[68]  W. Katon,et al.  Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[69]  M. Perry,et al.  Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer , 2010, Psycho-oncology.

[70]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[71]  P. Jean-Pierre,et al.  Cancer-related fatigue: the scale of the problem. , 2007, The oncologist.

[72]  R. Spitzer,et al.  The Patient Health Questionnaire-2: Validity of a Two-Item Depression Screener , 2003, Medical care.

[73]  D. Christiansen,et al.  Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. , 2000, Blood.

[74]  H. Dastani,et al.  Impact of Nivolumab versus Docetaxel on Health‐Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  K. Kroenke,et al.  Screening for major depression in cancer outpatients , 2011, Cancer.